1. US FDA. 1996. Guidance concerning demonstration of comparability of human biological products, including therapeutic biotechnology-derived products.
2. EMEA. 2007. Guideline on comparability of biotechnology-derived medicinal products after a change in the manufacture process. EMEA/CHAMP/BMWP/101695/2006.
3. ICDRA. 2002. Proceedings of the Tenth International Conference of Drug Regulator Authorities (ICDRA), Regulating biotechnology products, Hong Kong, China, 24–27 June 2002.
4. US FDA Guidance. 1992. Statistical procedures for bioequivalence studies using a standard two-treatment crossover design.
5. US FDA. Guidance for industry. Statistical approaches to establishing bioequivalence. 2001